SavedAdd your journal

Journals / Eurasian Journal of Medical Investigation / 2021 / Cilt: 5 - Sayı: 4

Adenoid Cystic Carcinoma; A Single Center 15 Years Experience and Literature Review

Celal Alandag
Seher Nazli Kazaz
Bengu Cobanoglu
Pages
491–495
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

We analyzed the demographic data of these 17 patients, effects of inflammatory markers on overall survival (OS) and progression-free survival (PFS).

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: Adenoid cystic carcinoma (ACC) is a rare tumor that arises from the salivary glands.
📊
Key Findings & Data:Since it is rare, there are no consensus recommendations on its treatment strategy.
💡
Conclusion & Impact:We analyzed the demographic data of these 17 patients, effects of inflammatory markers on overall survival (OS) and progression-free survival (PFS).
🔬Design:Research Article
📍Scope:2005 Verileri
⚙️Variables:Domain Parameters

Abstract

Objectives: Adenoid cystic carcinoma (ACC) is a rare tumor that arises from the salivary glands. Since it is rare, there are no consensus recommendations on its treatment strategy. Surgery, radiotherapy (RT), and systemic treatments are options We aimed to evaluate the treatment outcomes and prognostic factors in ACC. Methods: In this retrospective study; 17 ACC patients were included who were diagnosed with between January 2005 and April 2020 in Karadeniz Technical University Faculty of Medicine. We analyzed the demographic data of these 17 patients, effects of inflammatory markers on overall survival (OS) and progression-free survival (PFS). Results: Ten women and seven men were included in this study. At the diagnosis, 6 patients were metastatic, 5 of them had received chemotherapy. There was no statistical difference in overall survival according to neutrophil/lymphocyte ratio (N/L) and platelet/lymphocyte (T/L) ratio. Conclusion: Primary surgery is the most effective treatment, If possible, metastasectomy should be performed. ACC is a chemotherapy-resistant disease, so chemotherapy should only be given to metastatic, symptomatic, and fıt patients. We did not detect the prognostic effect of T/L and N/L in a limited number of ACC samples.

🔖

Cite This Article

Alandag, C., Kazaz, S. N., Cobanoglu, B. (2022). Adenoid Cystic Carcinoma; A Single Center 15 Years Experience and Literature Review. Eurasian Journal of Medical Investigation, Cilt: 5 - Sayı: 4, 491–495. https://ajindex.com/articles/508620

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Ellington CL, Goodman M, Kono SA, Grist W, Wadsworth T, Chen AY, et al. Adenoid cystic carcinoma of the head and neck: Incidence and survival trends based on 1973-2007 surveillance, epidemiology, and end results data. Cancer 2012;118:4444–51
  2. Demircan V, Akmansu M, Aydil U, Türkcan A, Au D, Sayar E. Sin- gle institutional experience of head and neck adenoid cystic carcinomas. Otorhinolaryngol Head Neck Surg 2018;3:2–4
  3. Park I, Lim SN, Dok HY, Park H, Sun B, Pil HL, et al. Metastasec- tomy for hepatic metastases from adenoid cystic carcinoma of the trachea. Gut Liver 2009;3:127–9
  4. Liu D, Labow DM, Dang N, Martini N, Bains M, Burt M, et al. Pulmonary metastasectomy for head and neck cancers. Ann Surg Oncol 1999;6:572–8
  5. Mimica X, McGill M, Hay A, Karassawa Zanoni D, Shah JP, Wong RJ, et al. Distant metastasis of salivary gland cancer: Incidence, management, and outcomes. Cancer 2020;126:2153–62
  6. Laurie SA, Ho AL, Fury MG, Sherman E, Pfister DG. Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review. Lancet Oncol 2011;12:815–24
  7. Mannelli G, Cecconi L, Fasolati M, Santoro R, Franchi A, Gallo O. Parotid adenoid cystic carcinoma: Retrospective single in- stitute analysis. Am J Otolaryngol 2017;38:394–400
  8. Brkic FF, Kadletz L, Jank B, Cede J, Seemann R, Schneider S, et al. Pretreatment assessment of hematologic and inflammato- ry markers in adenoid cystic carcinoma: neutrophil/lympho- cyte ratio is associated with multiple recurrences. Oral Surg Oral Med Oral Pathol Oral Radiol 2019;127:408–16
  9. Kokemueller H, Eckardt A, Brachvogel P, Hausamen JE. Ade- noid cystic carcinoma of the head and neck - A 20 years expe- rience. Int J Oral Maxillofac Surg 2004;33:25–31
  10. Amit M, Na’ara S, Trejo–Leider L, Ramer N, Burstein D, Yue M, et al. Defining the surgical margins of adenoid cystic carcinoma and their impact on outcome: An international collaborative study. Head Neck 2017;39:1008–14
  11. Tirelli G, Capriotti V, Sartori G, Tofanelli M, Marcuzzo AV. Prima- ry adenoid cystic carcinoma of the frontal sinus: case descrip- tion of a previously unreported entity and literature review. Ear Nose Throat J 2019;98:E8–12
  12. Turri–Zanoni M, Salzano G, Lambertoni A, Giovannardi M, Kar- ligkiotis A, Battaglia P, et al. Prognostic value of pretreatment peripheral blood markers in paranasal sinus cancer: Neutro- phil-to-lymphocyte and platelet-to-lymphocyte ratio. Head N